Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile B Kiss, A Horváth, Z Némethy, É Schmidt, I Laszlovszky, G Bugovics, ... Journal of Pharmacology and Experimental Therapeutics 333 (1), 328-340, 2010 | 403 | 2010 |
Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats J Laszy, I Laszlovszky, I Gyertyán Psychopharmacology 179, 567-575, 2005 | 164 | 2005 |
Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying I Gyertyan Behavioural pharmacology 6 (1), 24-31, 1995 | 161 | 1995 |
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents I Gyertyán, B Kiss, K Sághy, J Laszy, G Szabó, T Szabados, LI Gémesi, ... Neurochemistry international 59 (6), 925-935, 2011 | 159 | 2011 |
mCPP-induced anxiety in the light-dark box in rats–a new method for screening anxiolytic activity A Bilkei-Gorzo, I Gyertyan, G Levay Psychopharmacology 136, 291-298, 1998 | 159 | 1998 |
Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and … R Zimnisky, G Chang, I Gyertyán, B Kiss, N Adham, C Schmauss Psychopharmacology 226, 91-100, 2013 | 126 | 2013 |
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology JC Neill, B Grayson, B Kiss, I Gyertyán, P Ferguson, N Adham European Neuropsychopharmacology 26 (1), 3-14, 2016 | 115 | 2016 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model V Duric, M Banasr, T Franklin, A Lepack, N Adham, B Kiss, I Gyertyán, ... International Journal of neuropsychopharmacology 20 (10), 788-796, 2017 | 103 | 2017 |
Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors É Ágai-Csongor, G Domány, K Nógrádi, J Galambos, I Vágó, GM Keserű, ... Bioorganic & Medicinal Chemistry Letters 22 (10), 3437-3440, 2012 | 101 | 2012 |
Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats K Gál, I Gyertyán Drug and alcohol dependence 81 (1), 63-70, 2006 | 87 | 2006 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression M Papp, P Gruca, M Lason-Tyburkiewicz, N Adham, B Kiss, I Gyertyán Behavioural Pharmacology 25 (5 and 6), 567-574, 2014 | 82 | 2014 |
Critical evaluation of the use of dogs in biomedical research and testing in Europe N Hasiwa, J Bailey, P Clausing, M Daneshian, S Farkas, I Gyertyán, ... | 78 | 2011 |
Classification and reporting of severity experienced by animals used in scientific procedures: FELASA/ECLAM/ESLAV Working Group report D Smith, D Anderson, AD Degryse, C Bol, A Criado, A Ferrara, NH Franco, ... Laboratory animals 52 (1_suppl), 5-57, 2018 | 72 | 2018 |
The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia DJG Watson, MV King, I Gyertyán, B Kiss, N Adham, KCF Fone European Neuropsychopharmacology 26 (2), 208-224, 2016 | 72 | 2016 |
Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference I Gyertyán, K Gál Neuroreport 14 (1), 93-98, 2003 | 70 | 2003 |
Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats K Gál, I Gyertyán Brain research bulletin 61 (6), 595-601, 2003 | 63 | 2003 |
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural … I Gyertyán, K Sághy, J Laszy, O Elekes, R Kedves, LI Gémesi, G Pásztor, ... Naunyn-Schmiedeberg's archives of pharmacology 378, 529-539, 2008 | 62 | 2008 |
Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain … N Seneca, SJ Finnema, I Laszlovszky, B Kiss, A Horváth, G Pásztor, ... Psychopharmacology 218, 579-587, 2011 | 57 | 2011 |
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists G Szabó, B Varga, D Páyer-Lengyel, A Szemzo, P Erdélyi, K Vukics, ... Journal of medicinal chemistry 52 (14), 4329-4337, 2009 | 55 | 2009 |
Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats V Roman, I Gyertyan, K Saghy, B Kiss, Z Szombathelyi Psychopharmacology 226, 285-293, 2013 | 52 | 2013 |